Skip to content

Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Arena Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2017 Financial Results
- Etrasimod Phase 2 Data in UC Anticipated this Month - Ralinepag Phase 3 Clinical Program Expected to Begin in H2 2018 SAN DIEGO , March 14, 2018 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), today provided a corporate update and reported financial results for the fourth quarter and
View HTML
Toggle Summary Arena Pharmaceuticals to Announce Fourth Quarter and Full-Year 2017 Financial Results and Provide Corporate Update on Wednesday, March 14
SAN DIEGO , March 8, 2018 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), will announce its fourth quarter and full-year 2017 financial results on Wednesday, March 14, 2018 , before the open of the U.S. financial markets.  The Company will host a conference call and live webcast to
View HTML
Toggle Summary Arena Pharmaceuticals to Present Phase 1 and Preclinical Data on APD371 in Development for Treatment of Pain Associated with Crohn's Disease at American Pain Society Annual Scientific Summit
- Data from Phase 1 study of APD371 in healthy volunteers demonstrate safety and tolerability - Healthy volunteers did not exhibit psychotropic effects commonly seen with cannabinoids - Preclinical studies show thousand-fold selectivity for CB2 over CB1 receptors SAN DIEGO , March 1, 2018
View HTML
Toggle Summary Arena Pharmaceuticals Announces Changes to Board of Directors
SAN DIEGO , Feb. 16, 2018 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), today announced Scott H. Bice, Phillip M. Schneider , and Christine A. White , M.D. have indicated that they will be retiring from the Board of Directors at the time of Arena's next annual stockholders' meeting,
View HTML
Toggle Summary Arena Pharmaceuticals to Present at Upcoming Investor Conferences
SAN DIEGO , Feb. 6, 2018 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), today announced that that members of its senior management team will present at two upcoming investor conferences in New York City . LEERINK Partners 7 th Annual Global Healthcare Conference - Presenting on
View HTML
Toggle Summary Arena Pharmaceuticals to Host Key Opinion Leader Event on S1P Modulation and Etrasimod in Autoimmune Diseases on January 29 in New York City
- Jerold Chun, M.D., Ph.D. (Sanford Burnham Prebys), and Eric Gershwin, M.D. (UC Davis Health), to Present
View HTML
Toggle Summary Arena Pharmaceuticals to Present at the 36th Annual J.P. Morgan Healthcare Conference on January 10
SAN DIEGO , Dec. 21, 2017 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), today announced that Amit D. Munshi , the Company's President and Chief Executive Officer, will present a corporate update at the 36th Annual J.P. Morgan Healthcare Conference on Wednesday, January 10 , at 2:30
View HTML
Toggle Summary Arena Pharmaceuticals and Everest Medicines Enter into Development and Commercialization Partnership for Ralinepag and Etrasimod in China
Arena eligible to receive up to $224M, including upfront and milestone payments, in addition to royalties
View HTML
Toggle Summary Arena Pharmaceuticals Completes Full Enrollment in Etrasimod Phase 2 Clinical Study for Ulcerative Colitis
Data Readout Expected in Q1 2018
View HTML
Toggle Summary Arena Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2017 Financial Results
- Submitted Ralinepag FDA Meeting Request<br>- Expect to Complete Full Enrollment for Etrasimod Phase 2 Study in Ulcerative Colitis This Week<br>- Initiated Etrasimod Phase 2 Study in Primary Biliary Cholangitis
View HTML